NEW YORK , Sept. 13, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the exercise of a procurement option under its 75A50118C00019 (19C) contract with Biomedical Advanced Research and Development Authority (BARDA),

NEW YORK , Sept. 07, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that Dr. Phil Gomez , the Company’s Chief Executive Officer, will be a speaker at the NCT USA conference on September 8 , in Baltimore , Maryland. 

- Approximately $7 Million in International Sales of Oral TPOXX® in the Second Quarter – - Authorization of Additional $50 Million Share Repurchase Program - - Corpor ate Update Conference Call Today at 4:30 PM ET   NEW YORK , Aug. 05, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc.

NEW YORK , July 29, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 5 th , 2021.

NEW YORK , July 29, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into a collaboration with Oxford University in the United Kingdom ( UK ) to provide TPOXX®

NEW YORK , June 30, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it provided TPOXX® (tecovirimat) to Liverpool University Hospitals NHS Foundation Trust , in the United

-  Approximately $3 Million in International Sales of Oral TPOXX® in the First Quarter - - Approximately $7 Million in International Sales of Oral TPOXX® in April - - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK , May 06, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc.

- Important for Patients Who Cannot Swallow Oral Capsules - NEW YORK , May 04, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has filed a New Drug Application (NDA) with